Omar Dabbous

8.3k total citations · 2 hit papers
119 papers, 6.0k citations indexed

About

Omar Dabbous is a scholar working on Genetics, Molecular Biology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Omar Dabbous has authored 119 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Genetics, 29 papers in Molecular Biology and 29 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Omar Dabbous's work include Neurogenetic and Muscular Disorders Research (44 papers), Acute Myocardial Infarction Research (24 papers) and RNA modifications and cancer (21 papers). Omar Dabbous is often cited by papers focused on Neurogenetic and Muscular Disorders Research (44 papers), Acute Myocardial Infarction Research (24 papers) and RNA modifications and cancer (21 papers). Omar Dabbous collaborates with scholars based in United States, United Kingdom and France. Omar Dabbous's co-authors include Robert J. Goldberg, Keith A.A. Fox, Shaun G. Goodman, Kim A. Eagle, Frans Van de Werf, Christopher B. Granger, Frederick A. Anderson, Philippe Gabríel Steg, Marcus Flather and Álvaro Avezum and has published in prestigious journals such as The Lancet, JAMA and Circulation.

In The Last Decade

Omar Dabbous

107 papers receiving 5.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Validated Prediction Model for All Forms of Acute Coronary Syndrome

2004 1.2k citations Omar Dabbous et al. profile →
Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE)

2006 1.1k citations Omar Dabbous, Frederick A. Anderson et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Omar Dabbous	3.8k	1.7k	1.3k	557	521	119	6.0k
Hicham Skali	5.8k 1.5×	1.2k 0.7×	1.5k 1.1×	656 1.2×	510 1.0×	157	8.7k
Maarten J. Cramer	4.5k 1.2×	1.1k 0.6×	960 0.7×	421 0.8×	307 0.6×	273	6.2k
Juan Sanchís	5.2k 1.4×	1.7k 1.0×	1.7k 1.3×	381 0.7×	396 0.8×	414	7.3k
Oscar C. Marroquin	2.0k 0.5×	1.7k 1.0×	784 0.6×	303 0.5×	321 0.6×	127	4.3k
Andrew T. Yan	5.4k 1.4×	1.8k 1.0×	2.1k 1.5×	536 1.0×	409 0.8×	298	7.4k
Shun Kohsaka	4.1k 1.1×	2.1k 1.2×	830 0.6×	240 0.4×	401 0.8×	429	6.4k
Nic J.G.M. Veeger	3.0k 0.8×	1.4k 0.8×	305 0.2×	362 0.6×	253 0.5×	234	7.2k
Hussein R. Al‐Khalidi	4.4k 1.2×	1.7k 1.0×	2.0k 1.5×	544 1.0×	88 0.2×	136	6.6k
Iain Squire	5.3k 1.4×	1.2k 0.7×	747 0.6×	1.5k 2.8×	248 0.5×	190	8.8k
Hans Rickli	4.0k 1.0×	1.6k 0.9×	801 0.6×	143 0.3×	357 0.7×	191	5.7k

Countries citing papers authored by Omar Dabbous

Since Specialization

Citations

This map shows the geographic impact of Omar Dabbous's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Omar Dabbous with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Omar Dabbous more than expected).

Fields of papers citing papers by Omar Dabbous

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Omar Dabbous. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Omar Dabbous. The network helps show where Omar Dabbous may publish in the future.

Co-authorship network of co-authors of Omar Dabbous

This figure shows the co-authorship network connecting the top 25 collaborators of Omar Dabbous. A scholar is included among the top collaborators of Omar Dabbous based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Omar Dabbous. Omar Dabbous is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Drummond, Michael, Omar Dabbous, Mondher Toumi, et al.. (2024). Real-world evidence for coverage determination of treatments for rare diseases. Orphanet Journal of Rare Diseases. 19(1). 47–47. 6 indexed citations

Tizzano, Eduardo F., Susana Quijano-Roy, Laurent Servais, et al.. (2024). Outcomes for patients in the RESTORE registry with spinal muscular atrophy and four or more SMN2 gene copies treated with onasemnogene abeparvovec. European Journal of Paediatric Neurology. 53. 18–24.

Patel, Anish, et al.. (2024). Risdiplam utilization, adherence, and associated health care costs for patients with spinal muscular atrophy: a United States retrospective claims database analysis. Orphanet Journal of Rare Diseases. 19(1). 494–494. 1 indexed citations

Servais, Laurent, et al.. (2024). 161P Long-term safety of onasemnogene abeparvovec for patients with spinal muscular atrophy: real-world findings from the RESTORE Registry. Neuromuscular Disorders. 43. 104441.596–104441.596.

Saleh, Shadi, Omar Dabbous, Sean D. Sullivan, et al.. (2023). A practical approach for adoption of a hub and spoke model for cell and gene therapies in low- and middle-income countries: framework and case studies. Gene Therapy. 31(1-2). 1–11. 4 indexed citations

Yang, Min, et al.. (2023). Health Care Resource Utilization and Costs for Patients with Spinal Muscular Atrophy: Findings from a Retrospective US Claims Database Analysis. Advances in Therapy. 40(10). 4589–4605. 8 indexed citations

Yang, Min, et al.. (2023). Patient and Caregiver Outcomes After Onasemnogene Abeparvovec Treatment: Findings from the Cure SMA 2021 Membership Survey. Advances in Therapy. 40(12). 5315–5337. 4 indexed citations

Toumi, Mondher, Omar Dabbous, Samuel Aballéa, et al.. (2023). Recommendations for economic evaluations of cell and gene therapies: a systematic literature review with critical appraisal. Expert Review of Pharmacoeconomics & Outcomes Research. 23(5). 483–497. 6 indexed citations

Dabbous, Omar, et al.. (2022). Real-world Outcomes of Nusinersen Alone and Onasemnogene Abeparvovec (OA) Alone or with Prior Nusinersen in Pediatric Patients with Spinal Muscular Atrophy (SMA): Interim Analysis of a US Retrospective Chart Review Study (P18-5.002). Neurology. 98(18_supplement). 1 indexed citations

10.

Servais, Laurent, John Day, Darryl C. De Vivo, et al.. (2020). Real-World Treatment Patterns and Outcomes in Patients with Spinal Muscular Atrophy Collected from the RESTORE Registry (2470). Neurology. 94(15_supplement).

11.

Finkel, Richard S., John Day, Darryl C. De Vivo, et al.. (2020). RESTORE: A Prospective Multinational Registry of Patients with Genetically Confirmed Spinal Muscular Atrophy - Rationale and Study Design. Journal of Neuromuscular Diseases. 7(2). 145–152. 26 indexed citations

12.

Awano, Hiroyuki, et al.. (2020). PMU36 COST-UTILITY ANALYSIS OF SINGLE DOSE GENE-REPLACEMENT THERAPY FOR SPINAL MUSCULAR ATROPHY TYPE 1 COMPARED TO CHRONIC NUSINERSEN TREATMENT IN JAPAN. Value in Health. 23. S239–S239. 3 indexed citations

13.

Dabbous, Omar, Douglas M. Sproule, Douglas E. Feltner, et al.. (2019). Event-Free Survival and Motor Milestone Achievement Following AVXS-101 and Nusinersen Interventions Contrasted to Natural History for Type I Spinal Muscular Atrophy Patients (S25.005). Neurology. 92(15_supplement). 4 indexed citations

14.

Dean, Ralph A., et al.. (2019). PBI1 THE VALUE OF ONASEMNOGENE ABEPARVOVEC (AVXS-101) AS A COST-EFFECTIVE GENE REPLACEMENT THERAPY FOR SPINAL MUSCULAR ATROPHY TYPE 1 IN IMPROVING SURVIVAL, HEALTHCARE RESOURCE UTILIZATION, AND MOTOR FUNCTION. Value in Health Regional Issues. 19. S11–S11. 1 indexed citations

15.

Rémuzat, C., et al.. (2019). PNS12 FACTORS TO BE CONSIDERED TO ENSURE ACCEPTABILITY OF HISTORICALLY CONTROLLED STUDIES BY HTA BODIES. Value in Health. 22. S764–S765. 1 indexed citations

16.

Dabbous, Omar, et al.. (2019). PRO51 COST-EFFECTIVENESS AND BUDGET IMPACT OF ONASEMNOGENE ABEPARVOVEC FOR SPINAL MUSCULAR ATROPHY TYPE 1: POST-HOC ANALYSIS OF A MODEL DEVELOPED BY ICER. Value in Health. 22. S850–S850. 1 indexed citations

17.

Malone, Daniel C., et al.. (2019). ND2 COST-UTILITY ANALYSIS OF SINGLE DOSE GENE-REPLACEMENT THERAPY FOR SPINAL MUSCULAR ATROPHY TYPE 1 COMPARED TO CHRONIC NUSINERSEN TREATMENT. Value in Health. 22. S42–S43. 2 indexed citations

18.

Dabbous, Omar, et al.. (2019). PRO22 BURDEN OF ILLNESS OF SPINAL MUSCULAR ATROPHY: AN UPDATE. Value in Health. 22. S339–S339.

19.

Spiegel, Brennan, Lewis R. Roberts, Reema Mody, et al.. (2010). The development and validation of a Nocturnal Gastro‐oesophageal Reflux Disease Symptom Severity and Impact Questionnaire for adults. Alimentary Pharmacology & Therapeutics. 32(4). 591–602. 19 indexed citations

20.

Hillson, Eric, et al.. (2008). Health Care Expenditures in Ulcerative Colitis: The Perspective of a Self-Insured Employer. Journal of Occupational and Environmental Medicine. 50(8). 969–977. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact